Document is current
Any future updates will be listed below
-
Authors
Mak, Blossom
Lin, Hui-Ming
Kwan, Edmond M.
Fettke, Heidi
Tran, Ben
Davis, Ian D.
Mahon, Kate
Stockler, Martin R.
Briscoe, Karen
Marx, Gavin
Zhang, Alison
Crumbaker, Megan
Tan, Winston
Huynh, Kevin
Meikle, Thomas G.
Mellett, Natalie A.
Hoy, Andrew J.
Du, Pan
Yu, Jianjun
Jia, Shidong
Joshua, Anthony M.
Waugh, David J.
Butler, Lisa M.
Kohli, Manish
Meikle, Peter J.
Azad, Arun A.
Horvath, Lisa G.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (GNT1196225, GNT1098647, Postgraduate Scholarship)
Cancer Institute NSW (10/TPG/1-04, 2018/TPG001)
Australian Prostate Cancer Research Centre-New South Wales
Prostate Cancer Foundation of Australia (Revolutionary Team Award MRTA3)
Cancer Council NSW (PG 10-01)
Cancer Council South Australia (PRF1117)
Victorian Government’s Operational Infrastructure Support Program
National Institutes of Health (RO1-CA212097)
Australian Government Department of Education, Skills and Employment (RTP Scholarship, RTP Scholarship)
University of Sydney (Merit Award)
Monash University (Postgraduate Publications Award, Postgraduate Scholarship)
Victorian Cancer Agency (CRF14009)
Astellas Pharma AU (Investigator-Initiated Grant)
ANZUP (Noel Castan Fellowship)
Twin Towers Services Community Foundation
- License Information
-
More Information
Article History
Received: 28 November 2021
Accepted: 14 February 2022
First Online: 25 March 2022
Declarations
:
: All participants provided written informed consent, with ethics approval obtained from Monash Health Institutional Review Board (15571X), Royal Prince Alfred Hospital Human Research Ethics Committee (X19-0320), and Mayo Clinic Institutional Review Board (09-1889).
: Not applicable.
: EMK: Honoraria—Janssen, Ipsen, Astellas Pharma, Research Review; Consulting or Advisory Role—Astellas Pharma, Janssen, Ipsen; Research Funding—Astellas Pharma, AstraZeneca; Travel & accommodation—Astellas Pharma, Pfizer, Ipsen, Roche.BT: Grants and personal fees—Amgen, AstraZeneca, Astellas, BMS, Janssen, Pfizer, MSD, Ipsen, Bayer; Personal fees—IQVIA, Sanofi, Tolmar, Novartis, Roche.IDD: Institutional funding—Pfizer, ANZUP Cancer Trials Group, Bayer, Astellas, Janssen, Movember Foundation, Merck Sharp & Dohme; AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Roche/Genentech, Seagen; Unremunerated chair of ANZUP Cancer Trials Group.AZ: Advisory Role—Astellas; Honoraria—Astellas; Grants and personal fees—Astra Zeneca, Pfizer; Personal fees—Merck Sharp & Dome, Bayer, Mundipharma, Janssen.AMJ.: Institutional funding—Pfizer, Astellas.AAA: Consultant—Astellas, Janssen, Novartis; Speakers Bureau—Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb; Merck Serono, Bayer; Honoraria—Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome; Scientific Advisory Board—Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome , Amgen, Noxopharm; Travel & accommodation—Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer; Investigator research funding—Astellas, Merck Serono, Astra Zeneca; Institutional research funding—Bristol Myers Squibb, Astra Zeneca, Aptevo Therapeutics, Glaxo Smith Kline, Pfizer, MedImmune, Astellas, SYNthorx, Bionomics, Sanofi Aventis, Novartis, Ipsen.LGH: Research funding—Astellas; Travel sponsorship—Janssen, Pfizer; Honoraria—Imagion Biosystems.All other authors declare that they have no competing interests.
